HZT-501
- Generic Name
- HZT-501
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
HZT-501 is under investigation by Horizon Therapeutics, Inc., a privately held biopharmaceutical company. It has entered Phase 3 clinical trials in March 2007 for reduction of the risk of development of ibuprofen-associated upper gastrointestinal (i.e., gastric and/or duodenal) ulcers. HZT-501 is a combination product including ibuprofen and the acid reducin...
- Indication
Investigated for use/treatment in pain (acute or chronic).
- Associated Conditions
- -
- Associated Therapies
- -
Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment
- Conditions
- Interventions
- First Posted Date
- 2009-09-25
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 86
- Registration Number
- NCT00984815
- Locations
- 🇺🇸
Altoona Center for Clinical Research Altoona Arthritis, Duncansville, Pennsylvania, United States
🇺🇸Illinois Bone & Joint Institute, Morton Grove, Illinois, United States
🇺🇸Metroplex Clinical Research Center, Dallas, Texas, United States
Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)
- Conditions
- Interventions
- First Posted Date
- 2008-02-12
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 179
- Registration Number
- NCT00613106
- Locations
- 🇺🇸
PRA International, San Diego, California, United States
Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated Ulcers
- First Posted Date
- 2007-03-22
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 627
- Registration Number
- NCT00450658
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.